These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 33984508)

  • 1. Dopamine neuron-specific LRRK2 G2019S effects on gene expression revealed by translatome profiling.
    Pallos J; Jeng S; McWeeney S; Martin I
    Neurobiol Dis; 2021 Jul; 155():105390. PubMed ID: 33984508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Drosophila hep pathway mediates Lrrk2-induced neurodegeneration.
    Yang D; Thomas JM; Li T; Lee Y; Liu Z; Smith WW
    Biochem Cell Biol; 2018 Aug; 96(4):441-449. PubMed ID: 29268033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
    Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
    Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary Amino Acids Impact LRRK2-Induced Neurodegeneration in Parkinson's Disease Models.
    Chittoor-Vinod VG; Villalobos-Cantor S; Roshak H; Shea K; Abalde-Atristain L; Martin I
    J Neurosci; 2020 Aug; 40(32):6234-6249. PubMed ID: 32605938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine Metabolism Pathway Is Downregulated in Dopaminergic Neurons with LRRK2 Overexpression in
    Cheng J; Wu BT; Liu HP; Lin WY
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Targets from LRRK2 Rescue Phenotypes.
    Toh J; Chua LL; Ho P; Sandanaraj E; Tang C; Wang H; Tan EK
    Cells; 2021 Jan; 10(1):. PubMed ID: 33466414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease.
    Islam MS; Nolte H; Jacob W; Ziegler AB; Pütz S; Grosjean Y; Szczepanowska K; Trifunovic A; Braun T; Heumann H; Heumann R; Hovemann B; Moore DJ; Krüger M
    Hum Mol Genet; 2016 Dec; 25(24):5365-5382. PubMed ID: 27794539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
    Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
    J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple Pathways of LRRK2-G2019S/Rab10 Interaction in Dopaminergic Neurons.
    Fellgett A; Middleton CA; Munns J; Ugbode C; Jaciuch D; Wilson LG; Chawla S; Elliott CJH
    J Parkinsons Dis; 2021; 11(4):1805-1820. PubMed ID: 34250948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.
    Cresto N; Gaillard MC; Gardier C; Gubinelli F; Diguet E; Bellet D; Legroux L; Mitja J; Auregan G; Guillermier M; Josephine C; Jan C; Dufour N; Joliot A; Hantraye P; Bonvento G; Déglon N; Bemelmans AP; Cambon K; Liot G; Brouillet E
    Neurobiol Dis; 2020 Feb; 134():104614. PubMed ID: 31605779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defects in mRNA Translation in LRRK2-Mutant hiPSC-Derived Dopaminergic Neurons Lead to Dysregulated Calcium Homeostasis.
    Kim JW; Yin X; Jhaldiyal A; Khan MR; Martin I; Xie Z; Perez-Rosello T; Kumar M; Abalde-Atristain L; Xu J; Chen L; Eacker SM; Surmeier DJ; Ingolia NT; Dawson TM; Dawson VL
    Cell Stem Cell; 2020 Oct; 27(4):633-645.e7. PubMed ID: 32846140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging.
    Chen X; Xie C; Tian W; Sun L; Zheng W; Hawes S; Chang L; Kung J; Ding J; Chen S; Le W; Cai H
    Mol Neurodegener; 2020 Feb; 15(1):12. PubMed ID: 32075681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
    Lin CH; Lin HI; Chen ML; Lai TT; Cao LP; Farrer MJ; Wu RM; Chien CT
    Hum Mol Genet; 2016 May; 25(10):1965-1978. PubMed ID: 26931464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of tyrosine hydroxylase-dopamine pathway in Parkinson's disease pathogenesis.
    Zhou ZD; Saw WT; Ho PGH; Zhang ZW; Zeng L; Chang YY; Sun AXY; Ma DR; Wang HY; Zhou L; Lim KL; Tan EK
    Cell Mol Life Sci; 2022 Nov; 79(12):599. PubMed ID: 36409355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation.
    Bono F; Mutti V; Devoto P; Bolognin S; Schwamborn JC; Missale C; Fiorentini C
    Neurobiol Aging; 2021 Mar; 99():65-78. PubMed ID: 33422895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice.
    Arbez N; He X; Huang Y; Ren M; Liang Y; Nucifora FC; Wang X; Pei Z; Tessarolo L; Smith WW; Ross CA
    Hum Mol Genet; 2020 Mar; 29(4):580-590. PubMed ID: 31813996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulated mRNA Translation in the G2019S LRRK2 and LRRK2 Knock-Out Mouse Brains.
    Kim JW; Yin X; Martin I; Xiong Y; Eacker SM; Ingolia NT; Dawson TM; Dawson VL
    eNeuro; 2021; 8(6):. PubMed ID: 34759048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
    Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P
    Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Petridi S; Middleton CA; Ugbode C; Fellgett A; Covill L; Elliott CJH
    G3 (Bethesda); 2020 Jun; 10(6):1903-1914. PubMed ID: 32321836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.